Romiplostim

What is Romiplostim?

Romiplostim (brand name Nplate, development designation AMG-531) is a recombinant fusion protein engineered by Amgen as the first-in-class 'peptibody' — a hybrid format in which four copies of an identical 14-amino-acid thrombopoietin-mimetic peptide (originally identified by Cwirla and colleagues at Affymax via phage-display screening for c-Mpl agonists) are covalently attached to a human IgG1 Fc domain. The Fc scaffold dramatically extends serum half-life (from minutes for the bare peptide to several days for the peptibody) by enabling FcRn-mediated recycling, and the four-peptide valency is required for productive dimerization of the c-Mpl receptor. Critically, the peptide module shares no sequence homology with endogenous thrombopoietin (TPO) — a deliberate design choice that emerged from the late-1990s pegylated-recombinant-megakaryocyte-growth-and-development-factor (PEG-rHuMGDF) catastrophe, in which a TPO-homologous biologic provoked cross-reactive neutralizing antibodies that left a small number of trial volunteers with persistent thrombocytopenia. Romiplostim binds c-Mpl (the TPO receptor, gene symbol MPL) at the same site as native TPO and triggers the same downstream JAK2/STAT5 and MAPK signaling cascades that drive megakaryocyte proliferation, differentiation, and platelet release, but a circulating anti-romiplostim antibody cannot cross-react with TPO because the underlying peptide sequences are unrelated. FDA-approved in August 2008 for chronic immune thrombocytopenia (ITP) in adults, with a 2018 pediatric extension (ages ≥1 year) and a January 2021 expansion to acute radiation syndrome — the latter awarded under the FDA Animal Rule on the strength of nonhuman primate survival data. Romiplostim is mechanistically distinct from eltrombopag (Promacta/Revolade), the small-molecule oral TPO-receptor agonist that binds a different transmembrane site on c-Mpl and is dosed daily by mouth.

What Romiplostim Is Investigated For

Romiplostim is one of two FDA-approved thrombopoietin-receptor agonists for chronic immune thrombocytopenia — the other is eltrombopag (Promacta/Revolade), a small-molecule oral agent. The two drugs share a clinical indication and a target receptor (c-Mpl) but differ on essentially every other axis: romiplostim is a parenteral peptibody given as a weekly subcutaneous injection at a starting dose of 1 mcg/kg titrated to 1–10 mcg/kg by platelet response; eltrombopag is a once-daily oral pill with strict food-timing rules (calcium and other polyvalent cations interfere with absorption). The pivotal evidence for romiplostim in chronic ITP is the parallel pair of Phase 3 trials reported by Kuter and colleagues in Lancet 2008, which randomized splenectomised and non-splenectomised adults with platelet counts ≤30×10⁹/L 2:1 to romiplostim or placebo for 24 weeks; durable platelet response (≥50×10⁹/L for ≥6 of the last 8 weeks) was achieved by 38% of splenectomised and 61% of non-splenectomised romiplostim patients vs 0% and 5% of placebo patients respectively. Bussel et al. NEJM 2006 was the first-in-human Phase 1/2 demonstration that AMG-531 produced dose-dependent platelet responses in chronic ITP. Long-term follow-up (Kuter 2013, up to 5 years of treatment) showed sustained platelet responses with no new safety signals. The pediatric Phase 3 (Tarantino et al., Lancet 2016) extended approval to children ≥1 year. The 2021 acute radiation syndrome indication is the rarer kind of FDA approval — granted under the Animal Rule because human efficacy trials are ethically and logistically impossible — based on rhesus macaque survival data showing that single-dose romiplostim after lethal-range irradiation reduced 60-day mortality. Honest caveats: bone marrow reticulin deposition was an early concern that has not translated into clinically significant myelofibrosis at the rates initially feared, but bone marrow monitoring remains part of long-term surveillance; thromboembolic events occur at modestly elevated rates in some series; and rebound thrombocytopenia (platelet count falling below pre-treatment baseline) can occur on abrupt discontinuation. The ASH 2019 ITP guidelines (Neunert et al., Blood Adv) recommend TPO-receptor agonists — romiplostim or eltrombopag — as second-line therapy for adults with corticosteroid-refractory ITP, with the choice between them driven by patient preference (oral vs injectable), comorbidities, and access.

History & Discovery

Romiplostim's history starts with a near-disaster. In the late 1990s, two recombinant thrombopoietin biologics — full-length glycosylated TPO (rHuTPO, Genentech) and a truncated pegylated megakaryocyte growth and development factor (PEG-rHuMGDF, Amgen) — were in late-stage clinical development for chemotherapy-induced and ITP-related thrombocytopenia. Both showed clear pharmacodynamic effects on platelet counts. Both ran into a catastrophic immunogenicity problem: in healthy volunteers being dosed with PEG-rHuMGDF for the purpose of harvesting apheresis platelets for transfusion, a fraction developed neutralising antibodies that cross-reacted with their own endogenous thrombopoietin and produced persistent, transfusion-dependent thrombocytopenia. Both programs were halted. The TPO-mimetic field went silent for several years. The escape route came from an Affymax phage-display screen. Cwirla, Balasubramanian, Duffin, Wagstrom, Gates, Singer, Davis, Tansik, Mattheakis, Boytos, Schatz, Baccanari, Wrighton, Barrett and Dower, working with Amgen collaborators, panned random 14-mer peptide libraries against the extracellular domain of c-Mpl. The 1997 Science paper that came out of this work identified the IEGPTLRQWLAARA-class peptide and showed it was a full TPO agonist — a dissociation constant of roughly 2 nanomolar for the monomer, and, once dimerized, an EC50 of 100 picomolar in a TPO-responsive cell proliferation assay, equipotent to the 332-amino-acid natural cytokine — and crucially, with no sequence relationship to native TPO. This decoupling was the conceptual key: a peptide of independent sequence could mimic the receptor pharmacology without inheriting the immunogenic cross-reactivity that had killed PEG-rHuMGDF. Amgen took the peptide forward as AMG-531. Rather than synthesise a short peptide that would be cleared in minutes, the team adopted the 'peptibody' format — four copies of the peptide tethered to a human IgG1 Fc — to extend half-life via FcRn recycling and to provide the receptor-clustering valency needed for full agonism. Broudy and Lin (Cytokine 2004) provided the in vitro confirmation that AMG-531 stimulated megakaryopoiesis through Mpl. The first-in-human Phase 1/2 in chronic ITP was reported by Bussel and colleagues in NEJM 2006: dose-dependent platelet responses, no immunogenicity catastrophe, and a clean safety profile in early patients. The pivotal Phase 3 program followed quickly: Kuter and colleagues, Lancet 2008, randomised splenectomised and non-splenectomised adults with chronic ITP to weekly romiplostim or placebo for 24 weeks and showed durable platelet responses in 38% and 61% of the treated arms respectively, against essentially no responders on placebo. The FDA approved Nplate (romiplostim) in August 2008 for chronic ITP in adults who had failed corticosteroids, immunoglobulins, or splenectomy. The label initially restricted the drug to clinic-administered weekly injections under the Nplate NEXUS REMS program, primarily to support the bone-marrow-monitoring obligations imposed by the early reticulin-fiber concern. The pediatric Phase 3 (Tarantino et al., Lancet 2016) supported a 2018 extension to children ≥1 year with chronic ITP. Long-term safety follow-up (Kuter 2013 Br J Haematol; multiple registries) gradually de-escalated the marrow-fibrosis concern, and the REMS program was modified to allow self-administration for appropriately trained patients. The more unusual chapter is the 2021 acute radiation syndrome approval. The U.S. Strategic National Stockpile had been investing in radiologic/nuclear emergency countermeasures since the early 2000s; thrombocytopenia after lethal-range radiation exposure had no specific countermeasure. Amgen, the U.S. Biomedical Advanced Research and Development Authority (BARDA), and SRI International ran a series of nonhuman primate studies culminating in a randomized, blinded, placebo-controlled survival trial in 80 rhesus monkeys irradiated at 6.8 Gy (an LD70/60 dose), in which a single 5 mcg/kg subcutaneous dose of romiplostim raised 60-day survival from 32.5% to 72.5%. The 10 mcg/kg human dose was then derived by population modeling rather than measured in animals. Under the FDA Animal Rule, Nplate was approved for hematopoietic acute radiation syndrome in adults and pediatric patients (including neonates) in January 2021. It was the first thrombopoietic agent ever approved under the Animal Rule, and the first peptibody to receive a radiologic-emergency indication. Commercially, Nplate has been one of Amgen's steadier specialty assets — chronic ITP is a small population, but a high-touch one with sustained therapy. Eltrombopag (Promacta in the US, Revolade in Europe), the small-molecule oral TPO-receptor agonist developed by GlaxoSmithKline and now marketed by Novartis, has been the dominant competitive force; the two drugs split the chronic ITP market roughly along route-of-administration preference lines. Avatrombopag (Doptelet, originally AkaRx/Eisai/Dova/now Sobi) entered the field later as an oral small-molecule TPOR agonist for chronic liver disease–associated thrombocytopenia and has more recently expanded into chronic ITP.

How It Works

Platelets are made by giant bone marrow cells called megakaryocytes. The hormone thrombopoietin (TPO) tells those cells to grow, mature, and shed platelets into the blood by binding a receptor called c-Mpl on their surface. Romiplostim is a designer molecule that binds the same c-Mpl receptor and pushes the same buttons as natural TPO — but it is built from a short peptide that bears no resemblance to TPO itself, attached to an antibody-like Fc tail that lets it last for days in the bloodstream. By weekly injection, it drives the marrow to produce more platelets, restoring counts in patients whose immune systems are destroying their platelets faster than the body can replace them.

Romiplostim's mechanism rests on three pieces: the peptide, the receptor, and the Fc scaffold. The peptide module was discovered by Cwirla and colleagues at Affymax (Science 1997) using random-peptide phage-display libraries panned against the extracellular domain of c-Mpl, the receptor for thrombopoietin. They identified a 14-residue consensus sequence (around the IEGPTLRQWLAARA motif) that bound c-Mpl with a dissociation constant of approximately 2 nanomolar and, in dimeric form, produced an EC50 of 100 picomolar in cell-based proliferation assays — full TPO-equivalent agonism despite zero sequence homology to native TPO. This was a foundational result for the TPO field and for receptor-agonist peptide design generally — proof that a small synthetic peptide could fully mimic a 332-amino-acid four-helical-bundle cytokine at its receptor. The receptor, c-Mpl (encoded by MPL), is a homodimeric type I cytokine receptor expressed on megakaryocyte progenitors, mature megakaryocytes, platelets, and hematopoietic stem cells. Native TPO binding induces receptor homodimerization and trans-activation of receptor-associated JAK2 kinases, which phosphorylate cytoplasmic tyrosines on c-Mpl and recruit STAT5 (the dominant transcriptional output, driving megakaryocyte lineage commitment and proliferation), PI3K/Akt (cell-survival signaling), and the Ras/Raf/MEK/MAPK cascade (proliferation and differentiation cofactors). Romiplostim, by virtue of its tetravalent peptide presentation on the Fc dimer, drives c-Mpl dimerization (and in some membrane contexts higher-order clustering) at the same extracellular site as native TPO and triggers the identical downstream signaling. Broudy and colleagues (Cytokine 2004) confirmed that AMG-531 acts on Mpl in cell-based megakaryopoiesis assays with kinetics matching the Cwirla peptide. The Fc scaffold is human IgG1 Fc and is responsible for the drug's pharmacokinetic profile. The naked 14-amino-acid TPO-mimetic peptide would be cleared from circulation within minutes by glomerular filtration and proteolytic degradation. Conjugation to Fc reduces renal clearance below the glomerular filtration cutoff and engages the neonatal Fc receptor (FcRn) salvage pathway, which recycles internalised IgG-class molecules back to the circulation rather than routing them to lysosomal degradation. The result is a serum half-life of approximately 3–4 days in patients with chronic ITP — long enough to support weekly subcutaneous dosing, short enough to allow rapid de-escalation if the platelet count overshoots. Each romiplostim molecule carries four copies of the peptide (two on each heavy chain of the Fc dimer), which both increases avidity for c-Mpl and may support higher-order receptor clustering implicated in optimal STAT5 activation. The deliberate non-homology with native TPO is a design feature, not a coincidence. The earlier PEG-rHuMGDF (a pegylated truncated TPO-domain biologic) provoked cross-reactive antibodies in a fraction of healthy volunteers given the drug for platelet donation purposes; those antibodies neutralised endogenous TPO and produced persistent thrombocytopenia in some affected individuals. By choosing a peptide module identified through phage display rather than sequence-based engineering of TPO itself, the romiplostim program was insulated from this failure mode: any antibody response to romiplostim would not be expected to cross-react with the patient's own TPO, because the underlying peptide is structurally unrelated. This is the central biotech-history lesson the peptibody format was designed to absorb.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Romiplostim:

• 01Optimal duration of therapy and predictors of treatment-free remission — a subset of chronic ITP patients achieve durable platelet stability after a period of romiplostim and can discontinue, but the predictors are not well defined and the right tapering protocol is not established.
• 02Long-term cardiovascular and thromboembolic outcomes beyond 5–6 years of continuous therapy — registries are accumulating but are not yet definitive on the long-term thrombosis question.
• 03Role in chemotherapy-induced thrombocytopenia — substantially advanced but not closed. The RECITE Phase 3 (Al-Samkari, Kuter, Soff et al., NEJM 12 March 2026, PMID 41812193) showed 84% versus 36% of patients avoiding CIT-induced chemotherapy dose modification, and a Blood 'How I Treat' companion followed six months later (PMID 42406744). Two things remain open: Amgen's second pivotal trial PROCLAIM (NCT03937154, n=145, in non-small-cell lung, ovarian and breast cancer, primary completion March 2026) has not reported, and no FDA submission for a CIT indication has been announced. RECITE enrolled only gastrointestinal-cancer patients on oxaliplatin-based regimens, so generalisation beyond that setting rests on PROCLAIM. A 2026 target-trial emulation additionally reported a median overall survival of 13 months with romiplostim versus 9.5 months in controls (significant only in the metastatic subgroup), with 6-month VTE incidence of 10.0% versus 8.0% — the first outcome data beyond platelet counts.
• 04Role in MDS-related thrombocytopenia and post-HSCT thrombocytopenia — the MDS question is closer to answered than open, and answered unfavourably: a randomized placebo-controlled trial in low and intermediate-1 risk MDS was terminated for excess AML, and the label now warns that romiplostim increases blast counts and AML progression risk in some MDS patients. Post-HSCT is the live question. In the pediatric post-HSCT setting, a 2026 prospective single-arm trial (Karimizadeh et al., Transplant Cell Ther) of weekly subcutaneous romiplostim for up to 12 weeks in 47 children (median age 7) reported an 80.9% overall response rate with 42.6% complete responses, platelet-transfusion independence in 74.5%, no serious adverse events, and 82.3% six-month overall survival — described by its authors as the largest prospective pediatric study to date, and complemented by a separate 2026 randomized pilot giving romiplostim on days +1 and +8 after pediatric HSCT.
• 05Real-world H-ARS efficacy — by definition, the Animal Rule approval rests on nonhuman primate data; any human use will be in a mass-casualty radiation event, where post-hoc characterisation of efficacy will be observational at best.
• 06First-line ITP — the label restricts romiplostim to patients with an insufficient response to corticosteroids, immunoglobulins or splenectomy, but two Phase 3 trials are now testing it as an addition to first-line corticosteroids in newly diagnosed primary ITP (NCT05325593, romiplostim plus dexamethasone, primary completion October 2026; NCT07700238, romiplostim plus prednisolone, primary completion 2029). Whether earlier intervention raises the rate of durable treatment-free remission is the question that would most change practice.
• 07Severe aplastic anemia is moving from off-label use toward registrational evidence — beyond the 2026 single-arm meta-analysis, Qilu has a Phase 3 of Romiplostim N01 plus immunosuppressive therapy in treatment-naive severe aplastic anemia (NCT07345000, n=210), and a 2-year interim analysis of romiplostim plus immunosuppressive therapy as first-line aplastic-anemia treatment was published in 2026. The page's 'under investigation but not approved' framing understates how far this has progressed.
• 08Access landscape post-biosimilar entry — no biosimilar is approved in the US or EU, while Geropharm's GP40141 is in an active head-to-head Phase 3 and Qilu's Romiplostim N01 is in wide Chinese trial use. The implications for global access, particularly outside high-income healthcare systems, remain open.
• 09Comparative head-to-head data vs eltrombopag — most cross-class comparisons rely on indirect-comparison meta-analyses. Two 2026 large-scale observational analyses (propensity-score matching and the French FAITH target-trial emulation, PMIDs 42393361 and 41967713) have narrowed the gap on comparative thromboembolic risk, but a true randomised head-to-head in chronic ITP would still close the remaining efficacy question.

Forms & Administration

Romiplostim (Nplate) is supplied as a sterile lyophilized powder for reconstitution with sterile water for injection, in single-dose vials. It is administered exclusively by subcutaneous injection — there is no oral, intravenous, intramuscular, or transdermal form. The standard chronic ITP regimen is weekly subcutaneous injection at a starting dose of 1 mcg/kg actual body weight, titrated in 1 mcg/kg increments based on weekly platelet counts, to a target range of ≥50×10⁹/L (not normalisation), with a maximum dose of 10 mcg/kg/week. Once a stable platelet response is established, home administration by trained patients or caregivers is common practice, although the current label does not itself contain a self-administration provision. Pediatric dosing follows the same weight-based scheme. For acute radiation syndrome under the Animal Rule indication, a single 10 mcg/kg subcutaneous dose is given as soon as possible after suspected exposure to a myelosuppressive radiation dose. Nplate is a prescription-only biologic and not a controlled substance. It is frequently described as a restricted-distribution product, which was true at launch and has not been true for well over a decade: the restricted elements of the original Nplate NEXUS REMS — enrollment of prescribers, patients and institutions, and mandatory safety-data collection — were eliminated effective 7 December 2011, with the Medication Guide folded into approved labeling. The current prescribing information contains no REMS, NEXUS or restricted-distribution language at all. It is dispensed as a specialty biologic, not through a restricted channel.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Romiplostim is a prescription biologic dosed by weight and titrated against laboratory monitoring, and it is not a self-directed therapy. These figures describe the FDA-labeled regimen for reference; actual dosing requires a hematologist and weekly platelet counts during titration.

Timeline of Effects

Monitoring & Measurement

Common Questions

Who Romiplostim Is NOT For

Drug & Supplement Interactions

Romiplostim is a recombinant fusion protein cleared by intracellular catabolism, not by hepatic cytochrome P450 metabolism or renal excretion of intact drug. Pharmacokinetic drug-drug interactions through CYP enzymes, P-glycoprotein, or hepatic transporters are therefore not expected, and the FDA label does not list any specific drug-drug interaction warnings. Pharmacodynamic interactions are the relevant category. Concomitant systemic corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, rituximab, and other ITP-directed therapies may modify platelet responses to romiplostim. In clinical practice, romiplostim is often layered onto or used to bridge between these agents, and dose adjustments to either may be required as platelet counts shift. Concurrent eltrombopag is not a standard combination — both target the same receptor — and would be redundant rather than additive. Anticoagulants and antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor, warfarin, apixaban, rivaroxaban, edoxaban, dabigatran, low-molecular-weight heparins, fondaparinux) interact pharmacodynamically: a treated platelet count gives the anticoagulant a different bleeding-risk profile than the same dose in an untreated thrombocytopenic patient. Dose adjustment is not usually a romiplostim issue, but bleeding-risk reassessment is often required. No specific food or supplement interactions have been documented for romiplostim — unlike eltrombopag, which has well-characterised polyvalent-cation chelation that requires food separation, romiplostim is a subcutaneous biologic and is not subject to gastrointestinal absorption interactions. As always, the operative reference for specific concomitant-medication guidance is the institutional protocol and the current FDA prescribing information.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions